A week ago, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed expectations at US$52m, beating expectations by 24%. Adaptive Biotechnologies reported a statutory loss of US$0.20 per share, which - although not amazing - was much smaller than the analysts predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Our free stock report includes 3 warning signs investors should be aware of before investing in Adaptive Biotechnologies. Read for free now.NasdaqGS:ADPT Earnings and Revenue Growth May 4th 2025

Taking into account the latest results, the consensus forecast from Adaptive Biotechnologies' eight analysts is for revenues of US$216.0m in 2025. This reflects a meaningful 14% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 11% from last year to US$0.83. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$212.7m and losses of US$0.92 per share in 2025. Although the revenue estimates have not really changed Adaptive Biotechnologies'future looks a little different to the past, with a favorable reduction in the loss per share forecasts in particular.

View our latest analysis for Adaptive Biotechnologies

The average price target rose 8.8% to US$10.57, with the analysts signalling that the forecast reduction in losses would be a positive for the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Adaptive Biotechnologies, with the most bullish analyst valuing it at US$13.00 and the most bearish at US$7.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Adaptive Biotechnologies' growth to accelerate, with the forecast 19% annualised growth to the end of 2025 ranking favourably alongside historical growth of 13% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Adaptive Biotechnologies is expected to grow much faster than its industry.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Adaptive Biotechnologies going out to 2027, and you can see them free on our platform here..

Even so, be aware that  Adaptive Biotechnologies is showing  3 warning signs in our investment analysis, you should know about...

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments